Status:

COMPLETED

Topical Diclofenac for Hand-Foot Syndrome Prevention in Colorectal and Gastric Cancer on Capecitabine (DICLO-HFS)

Lead Sponsor:

Gazi University

Conditions:

Colorectal Cancer

Gastric Cancer (GC)

Eligibility:

All Genders

18+ years

Brief Summary

Hand-foot syndrome (HFS) is a frequent adverse effect of capecitabine, presenting with redness, swelling, pain, and peeling of the skin on the palms and soles. These symptoms may impair daily activiti...

Detailed Description

Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysesthesia, is a common dermatologic toxicity of fluoropyrimidine chemotherapy such as capecitabine. Clinically significant HFS (grade ≥2...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Age ≥18 years.
  • Histologically or cytologically confirmed colorectal or gastric cancer.
  • Planned capecitabine-based therapy (monotherapy or capecitabine plus oxaliplatin).
  • Planned starting capecitabine dose ≥2,000 mg/m²/day.
  • No prior systemic chemotherapy for the current malignancy.
  • Ability and willingness to attend weekly clinical assessments during treatment.
  • Written informed consent obtained.
  • Exclusion Criteria
  • Pre-existing dermatologic conditions affecting hands/feet (e.g., eczema, psoriasis) or peripheral neuropathy.
  • Sjögren's syndrome involving hands or feet.
  • Current or planned systemic NSAID use during capecitabine therapy.
  • Use of other HFS prophylaxis at baseline (e.g., topical NSAIDs other than diclofenac, pyridoxine).
  • Known hypersensitivity to diclofenac, aspirin, or other NSAIDs (e.g., history of asthma, urticaria, allergic reactions).
  • Planned initial capecitabine dose \<2,000 mg/m²/day.
  • Anticipated inability to comply with weekly follow-up assessments.

Exclusion

    Key Trial Info

    Start Date :

    July 30 2023

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    February 28 2024

    Estimated Enrollment :

    151 Patients enrolled

    Trial Details

    Trial ID

    NCT07177560

    Start Date

    July 30 2023

    End Date

    February 28 2024

    Last Update

    September 17 2025

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Ankara Etlik City Hospital

    Ankara, Turkey (Türkiye)

    2

    Gazi University

    Ankara, Turkey (Türkiye)